| International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Blood, The Journal of the American Society of Hematology 126 (3), 291-299, 2015 | 1359 | 2015 |
| Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis AR Folgueras, FM de Lara, AM Pendás, C Garabaya, F Rodríguez, ... Blood, The Journal of the American Society of Hematology 112 (6), 2539-2545, 2008 | 356 | 2008 |
| Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias MD Cappellini, J Porter, A El-Beshlawy, CK Li, JF Seymour, M Elalfy, ... haematologica 95 (4), 557, 2009 | 353 | 2009 |
| Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group A Oriol, S Vives, JM Hernández-Rivas, M Tormo, I Heras, C Rivas, ... Haematologica 95 (4), 589, 2010 | 343 | 2010 |
| Cytogenetic risk stratification in chronic myelomonocytic leukemia E Such, J Cervera, D Costa, F Solé, T Vallespí, E Luño, R Collado, ... Haematologica 96 (3), 375, 2011 | 312 | 2011 |
| Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome G Sanz, B Nomdedeu, E Such, T Bernal, M Belkaid, MT Ardanaz, V Marco, ... Blood 112 (11), 640, 2008 | 164 | 2008 |
| Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia CM Santamaría, MC Chillón, R García-Sanz, C Perez, MD Caballero, ... Blood, The Journal of the American Society of Hematology 114 (1), 148-152, 2009 | 135 | 2009 |
| Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care H Döhner, A Dolnik, L Tang, JF Seymour, MD Minden, RM Stone, ... Leukemia 32 (12), 2546-2557, 2018 | 127 | 2018 |
| Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents S Park, JF Hamel, A Toma, C Kelaidi, S Thépot, MD Campelo, V Santini, ... Journal of Clinical Oncology 35 (14), 1591-1597, 2017 | 108 | 2017 |
| Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry T Bernal, P Martínez-Camblor, J Sánchez-García, R de Paz, E Luño, ... Leukemia 29 (9), 1875-1881, 2015 | 108 | 2015 |
| Ventilatory support in critically ill hematology patients with respiratory failure R Molina, T Bernal, M Borges, R Zaragoza, J Bonastre, RM Granada, ... Critical Care 16, 1-7, 2012 | 105 | 2012 |
| Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors RG Urdinguio, AF Fernandez, A Moncada-Pazos, C Huidobro, ... Cancer research 73 (1), 395-405, 2013 | 95 | 2013 |
| Dose‐intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study … JM Ribera, O García, C Grande, J Esteve, A Oriol, J Bergua, ... Cancer 119 (9), 1660-1668, 2013 | 88 | 2013 |
| Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens JF Seymour, H Döhner, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... BMC cancer 17, 1-13, 2017 | 76 | 2017 |
| High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics CM Santamaría, MC Chillón, R García-Sanz, C Pérez, MD Caballero, ... Leukemia research 33 (12), 1706-1709, 2009 | 70 | 2009 |
| The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia C Santamaría, M Chillón, R García-Sanz, A Balanzategui, ME Sarasquete, ... Ferrata Storti Foundation, 2008 | 68 | 2008 |
| BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML) C Santamaría, MC Chillón, R García-Sanz, C Pérez, MD Caballero, ... Annals of hematology 89, 453-458, 2010 | 64 | 2010 |
| Effects of thinning on litterfall were found after years in a Pinus halepensis afforestation area at tree and stand levels FB Navarro, A Romero-Freire, T Del Castillo, A Foronda, MN Jiménez, ... Forest Ecology and Management 289, 354-362, 2013 | 60 | 2013 |
| Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a … J Briones, S Novelli, JA García-Marco, JF Tomás, T Bernal, C Grande, ... haematologica 99 (3), 505, 2014 | 57 | 2014 |
| Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials … JM Ribera, O García, A Oriol, C Gil, P Montesinos, T Bernal, ... Leukemia research 41, 12-20, 2016 | 56 | 2016 |
